Increased insulin-like growth factor (IGF)-II and IGF/IGF-binding protein ratio in prepubertal constitutionally tall children

被引:28
|
作者
Garrone, S
Radetti, G
Sidoti, M
Bozzola, M
Minuto, F
Barreca, A
机构
[1] Univ Genoa, Dept Endocrinol & Metab, Cattedra Endocrinol, I-16132 Genoa, Italy
[2] Univ Genoa, Ctr Excellence Biomed Res, I-16132 Genoa, Italy
[3] Hosp Bolzano, Dept Pediat, Bolzano, Italy
[4] Univ Pavia, Dept Pediat, I-27100 Pavia, Italy
来源
关键词
D O I
10.1210/jc.2002-020614
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The height of subjects with constitutionally tall stature (CTS) is at least 2 SD above the mean of subjects of the same age and sex. Apart from a few discordant data on the role of GH and its direct mediator, IGF-I, no studies have been conducted on other components of the IGF system, which also condition the bioavailability and activity of IGF-I. We, therefore, investigated the possibility that other components of the IGF system might play a role in determining the increased growth velocity seen in CTS. To this end, we evaluated the behavior not only of IGF-I but also of IGF-II, IGF-binding protein (IGFBP)-3, and acid-labile subunit, the subunits that constitute the main IGF complex in circulation (150-kDa complex), as well as of IGFBP-1 and IGFBP-2, which are negatively regulated by GH and, like IGFBP-3, able to influence the bioavailability of the IGFs. The study was performed on 22 prepubertal subjects affected by CTS (16 males and 6 females), aged 2.8-13.3 yr (6.8 +/- 0.5 yr, mean +/- SEM). Thirty-seven normal prepubertal subjects (16 males and 21 females) aged between 2.2 and 13.3 yr (6.7 +/- 0.5 yr), who were comparable in socioeconomic and nutritional terms, served as controls. From the auxological point of view, subjects with CTS differed significantly from controls only in terms of growth velocity (HV-SD score; CTS, 1.8 +/- 0.3; controls, 0.4 +/- 0.2; P < 0.0001) and height (H-SD score; CTS, 3.1 +/-0.1; controls, 0.4 +/- 0.2; P < 0.0001). The results demonstrated that the concentrations of IGF-I (27.3 +/- 2.0 nmol/liter), IGFBP-3 (66.9 +/- 3.8), and acid-labile subunit (216.8 +/- 13.6) in CTS-affected subjects were not significantly different from those determined in controls (25.0 +/- 2.9, 74.4 +/- 4.1, and 241.0 +/- 11.9, respectively). By contrast, IGF-II levels proved significantly higher in CTS subjects (IGF-II: 87.2 +/- 3.4 vs. 52.4 +/- 2.3, P < 0.0001). Chromatographic analysis, performed after acid treatment of pooled sera, showed only the presence of normal 7.5-kDa IGF-11 in both CTS subjects and controls. In comparison with controls, CTS children showed a lower concentration of IGFBP-1 (1.6 +/- 0.3 vs. 4.1 +/- 0.7, P = 0.03) and a higher concentration of IGFBP-2 (14.3 +/- 1.8 vs. 9.6 +/- 1.1, P = 0.03). The IGFs (IGF-I and -II)/IGFBPs (-1 + -2 + -3) molar ratio was significantly higher (P < 0.0001) in CTS children than in controls. In particular, the IGF-II/IGFBP ratio (P < 0.0001) was responsible for the excess of the IGF peptide in relation to the concentrations of IGFBPs and, therefore, for the increase in the potentially bioactive free form of the IGFs. Moreover, the IGFBP-3/IGF molar ratio was significantly reduced, being less than 1 in CTS subjects (0.6 +/- 0.1 vs. 1.1 +/- 0.1), so that a quantity of IGF peptides lack sufficient IGFBP-3 to form the 150-kDa complex with which are normally sequestered in the vascular compartment. The data show that in CTS: 1) the most GH-dependent components of the IGF system are normal, consistent with the finding of a normal GH secretory state; 2) the less GH-dependent IGF-II is significantly increased, in agreement with the finding of a relationship between high levels of IGF-II and overgrowth in some syndromes; and 3) the IGF/IGFBP molar ratio is increased, and, therefore, a greater availability of free IGF for target tissues may be responsible for overgrowth in CTS.
引用
下载
收藏
页码:5455 / 5460
页数:6
相关论文
共 50 条
  • [21] Binding of insulin-like growth factor (IGF) I or II to IGF-binding protein-2 enables it to bind to heparin and extracellular matrix
    Arai, T
    Busby, W
    Clemmons, DR
    ENDOCRINOLOGY, 1996, 137 (11) : 4571 - 4575
  • [22] Ontogenic changes in the circulating concentrations of insulin-like growth factor (IGF)-I, IGF-II, and IGF-binding proteins in the chicken embryo
    Scanes, CG
    Thommes, RC
    Radecki, SV
    Buonomo, FC
    Woods, JE
    GENERAL AND COMPARATIVE ENDOCRINOLOGY, 1997, 106 (02) : 265 - 270
  • [23] Insulin-like growth factor (IGF)-I, IGF-II and IGF-binding protein (IGFBP)-3 levels in Arab subjects with coronary heart disease
    Akanji, A. O.
    Suresh, C. G.
    Al-Radwan, R.
    Fatania, H. R.
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2007, 67 (05): : 553 - 559
  • [24] Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 in girls with premature thelarche
    Sales, DS
    Moreira, AC
    Camacho-Hübner, C
    Ricco, RG
    Daneluzzi, JC
    Campos, AD
    Martinelli, CE
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2003, 16 (06): : 827 - 833
  • [25] THE ONTOGENY OF INSULIN-LIKE GROWTH-FACTOR (IGF) AND IGF-BINDING PROTEIN GENE-EXPRESSION IN THE RAT PANCREAS
    HOGG, J
    HILL, DJ
    HAN, VKM
    JOURNAL OF MOLECULAR ENDOCRINOLOGY, 1994, 13 (01) : 49 - 58
  • [26] PARTITION OF INSULIN-LIKE GROWTH-FACTOR (IGF)-BINDING SITES BETWEEN THE IGF-I AND IGF-II RECEPTORS AND IGF-BINDING PROTEINS IN THE HUMAN KIDNEY
    CHIN, E
    MICHELS, K
    BONDY, CA
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 78 (01): : 156 - 164
  • [27] Insulin-like growth factor-I (IGF-I) and IGF-binding proteins in children with nephrotic syndrome
    Lee, DY
    Park, SK
    Kim, JS
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (05): : 1856 - 1860
  • [28] Insulin-like growth factor (IGF)-I, IGF-binding protein-3 and colorectal adenomas in Japanese men
    Teramukai, S
    Rohan, T
    Lee, KY
    Eguchi, H
    Oda, T
    Kono, S
    JAPANESE JOURNAL OF CANCER RESEARCH, 2002, 93 (11): : 1187 - 1194
  • [29] Measurement of Insulin-like Growth Factor (IGF)-1 and IGF-Binding Protein 3 in Pediatric Multiple Sclerosis Patients
    Gombolay, Grace Y.
    Saxena, Shrishti
    Keyhanian, Kiandokht
    Gonzalez, Cindy T.
    Misra, Madhusmita
    Chitnis, Tanuja
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 12 - 13
  • [30] Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer
    Krajcik, RA
    Borofsky, ND
    Massardo, S
    Orentreich, N
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2002, 11 (12) : 1566 - 1573